SHANGHAI, March 13, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2025 and provided corporate updates.

FINANCIAL HIGHLIGHTS

   -- Total revenue of Junshi Biosciences was approximately RMB2,498 million in 
      2025, representing an increase of approximately 28% compared to 2024, 
      which was mainly due to the increase in revenue from sales of 
      pharmaceutical products, in particular the domestic sales revenue of the 
      company's core product, toripalimab, was approximately RMB2,068 million, 
      representing an increase of approximately 38% compared to 2024. 
 
   -- Total research and development ("R&D") expenses of the company were 
      approximately RMB1,384 million in 2025, representing an increase of 
      approximately 9% compared to 2024. The increase in R&D expenses was 
      mainly due to the company's focus on more competitive and innovative R&D 
      pipelines and accelerated clinical development in 2025. 
 
   -- Net cash inflow from financing activities was approximately RMB2,232 
      million, which fully covered the cash outflows in operating and investing 
      activities, leading to an increase in bank balances and cash. A 
      successful placing of new H shares on 20 June 2025 generated a net cash 
      inflow of approximately RMB940 million for the company. 
 
   -- As of the end of 2025, the company's aggregate balance of bank balances 
      and cash and financial products was approximately RMB3,195 million, 
      providing a relatively sufficient cash position to support the company's 
      development. 

BUSINESS HIGHLIGHTS

During 2025, our commitment to addressing "unmet medical needs" has driven original, innovative and breakthrough progress in the discovery, R&D and commercialization of innovative therapies and drugs through accelerating international development. Here are the notable achievements and milestones:

   -- Advancements in the pipeline: Junshi Biosciences' innovative R&D field 
      has expanded from monoclonal antibodies to the research and development 
      of various drug modalities, including small molecule drugs, polypeptide 
      drugs, antibody drug conjugates $(ADC)$, bi-specific or multi-specific 
      antibodies, bispecific antibody drug conjugates, fusion protein, nucleic 
      acid drugs and vaccines, as well as the exploration of next-generation 
      innovative therapies, including those for cancer and autoimmune diseases. 
      A total of four drugs have been commercialized, a number of products are 
      undergoing phase 3 clinical studies or in the stage of marketing 
      application, and various innovative drugs that are competitive in the 
      international market are undergoing accelerated clinical trials. 
 
          -- In January 2025, the indication of toripalimab for the treatment 
             of unresectable or metastatic melanoma after failure of standard 
             systemic therapy was approved by the National Medical Products 
             Administration of China (the "NMPA") for conversion from 
             conditional approval to regular approval. 
 
          -- In January 2025, the investigational new drug ("IND") application 
             for JS212 [a recombinant humanized epidermal growth factor 
             receptor ("EGFR") and human epidermal growth factor receptor 3 
             ("HER3") bispecific ADC] was accepted by the NMPA. It was approved 
             by the NMPA in March 2025. The IND application of JS212 
             multi-cohort combined drug application was approved by the NMPA in 
             November 2025. In December 2025, the IND application for JS212 for 
             the treatment of advanced solid tumors was approved by the U.S. 
             Food and Drug Administration ("FDA"). 
 
          -- In January 2025, the indication of VV116/JT001 (MINDEWEI) for the 
             treatment of adult patients with mild to moderate coronavirus 
             disease 2019 ("COVID-19") was approved by the NMPA for conversion 
             from conditional approval to regular approval. 
 
          -- In January 2025, the New Chemical Entity ("NCE") application for 
             toripalimab in combination with cisplatin and gemcitabine, for the 
             first-line treatment of adults with metastatic or recurrent, 
             locally advanced nasopharyngeal carcinoma ("NPC") and toripalimab, 
             as a single agent, for the treatment of adults with recurrent 
             unresectable or metastatic NPC with disease progression on or 
             after a platinum-containing chemotherapy was approved by the 
             Therapeutic Goods Administration of the Australian Government 
             Department of Health and Aged Care (the "TGA"). Toripalimab became 
             the first immuno-onocology treatment for NPC in Australia. 
 
          -- In February 2025, the IND application for JS213 (a PD-1 and 
             interleukin-2 ("IL-2") bifunctional antibody fusion protein) was 
             approved by the NMPA. 
 
          -- In March 2025, the supplemental new drug application (the "sNDA") 
             for toripalimab in combination with bevacizumab for the first-line 
             treatment for patients with unresectable or metastatic 
             hepatocellular carcinoma ("HCC") was approved by the NMPA. 
 
          -- In March 2025, the new drug application (the "NDA") for 
             toripalimab in combination with cisplatin and gemcitabine for the 
             first-line treatment of adult patients with recurrent, not 
             amenable to surgery or radiotherapy, or metastatic NPC was 
             approved by the Singapore Health Sciences Authority (the "HSA"). 
             Toripalimab became the first approved immuno-oncology treatment 
             for NPC in Singapore. 
 
          -- In April 2025, the sNDA for toripalimab for the first-line 
             treatment of unresectable or metastatic melanoma was approved by 
             the NMPA. This is the 12th indication of toripalimab approved in 
             Chinese Mainland. 
 
          -- In May 2025, the two sNDAs for the ongericimab injection (a 
             recombinant humanized anti-PCSK9 monoclonal antibody injection, 
             trade name: JUNSHIDA) for: 1) adult patients with heterozygous 
             familial hypercholesterolemia ("HeFH"); 2) alone or in combination 
             with ezetimibe, in adult patients with non-familial 
             hypercholesterolemia and mixed dyslipidemia who are 
             statin-intolerant or statins contraindicated, were approved by the 
             NMPA. Ongericimab became the first domestic PCSK9-targeted drug 
             approved for statin-intolerant patients. 
 
          -- In June 2025, the IND application for the JT118 injection 
             ("JT118") was accepted. It was approved by the NMPA in September 
             2025. JT118 is a "two-in-one" recombinant protein vaccine composed 
             of a tandem fusion of monkeypox virus antigens A35 (an 
             extracellular enveloped virus antigen) and M1 (an intracellular 
             mature virus antigen), and is intended mainly for the prevention 
             of monkeypox virus infection. 
 
          -- In June 2025, the indications of toripalimab for the first-line 
             treatment of NPC and the first-line treatment of esophageal 
             squamous cell carcinoma ("ESCC") were officially approved for 
             marketing in the United Arab Emirates (the "UAE") and Kuwait. 
 
          -- In August 2025, the sNDA for toripalimab in combination with 
             disitamab vedotin as the treatment of HER2-expressing (HER2 
             expression is defined as HER2 immunohistochemistry results of 1+, 
             2+, or 3+) locally advanced or metastatic UC was accepted by the 
             NMPA. 
 
          -- In September 2025 and October 2025, the two indications for 
             toripalimab in combination with cisplatin and gemcitabine for the 
             first-line treatment of adults with metastatic or recurrent, 
             locally advanced NPC, and toripalimab, as a single agent, for the 
             treatment of adults with recurrent, unresectable or metastatic NPC 
             with disease progression on or after a platinum-containing 
             chemotherapy were approved for marketing in Pakistan and Canada, 
             respectively. 
 
          -- In October 2025, the IND application for an open-label, two-arm, 
             randomized, active-controlled, phase 2/3 clinical study comparing 
             JS207 (recombinant humanized anti-PD-1/VEGF bispecific antibody), 
             to nivolumab for the neoadjuvant treatment of patients with stage 
             2/3, resectable, actionable genomic aberration (AGA)-negative, 
             non-small cell lung cancer ("NSCLC") was approved by the FDA. 
 
          -- In November 2025, a new indication of toripalimab in combination 
             with chemotherapy as first-line treatment of ESCC was approved in 
             Hong Kong SAR, China. 
 
          -- In November 2025, the multi-center, open-label, randomized 
             controlled phase 3 clinical study comparing JS001sc (toripalimab 
             injection for subcutaneous use) to toripalimab in combination with 
             chemotherapy for the first-line treatment of recurrent or 
             metastatic non-squamous NSCLC met its primary endpoints. 
 
          -- In December 2025, the NDA for JS005 (roconkibart injection, a 
             recombinant humanized anti-IL-17A monoclonal antibody injection), 
             for the treatment of adult patients with moderate to severe plaque 
             psoriasis who are candidates for systemic therapy or phototherapy 
             was accepted. 
 

(MORE TO FOLLOW) Dow Jones Newswires

March 13, 2026 09:54 ET (13:54 GMT)